156 related articles for article (PubMed ID: 1608013)
1. Current trends in blood component therapy: the evolution of a safer, more effective product.
Baranowski L
J Intraven Nurs; 1992; 15(3):136-51. PubMed ID: 1608013
[TBL] [Abstract][Full Text] [Related]
2. Current and future trends in transfusion therapy.
Rossetto CL; McMahon JE
J Pediatr Oncol Nurs; 2000 Jul; 17(3):160-73. PubMed ID: 10944864
[TBL] [Abstract][Full Text] [Related]
3. Pathogen reduction of blood components.
Solheim BG
Transfus Apher Sci; 2008 Aug; 39(1):75-82. PubMed ID: 18602343
[TBL] [Abstract][Full Text] [Related]
4. Toward reducing perioperative transfusions.
Joyce JA
AANA J; 2008 Apr; 76(2):131-7. PubMed ID: 18478819
[TBL] [Abstract][Full Text] [Related]
5. Blood component therapy.
Fasano R; Luban NL
Pediatr Clin North Am; 2008 Apr; 55(2):421-45, ix. PubMed ID: 18381094
[TBL] [Abstract][Full Text] [Related]
6. Blood transfusion.
Nerlich S
Aust Nurs J; 1998 Jun; 5(11):suppl i-iv. PubMed ID: 10639966
[TBL] [Abstract][Full Text] [Related]
7. Use of blood products and factor concentrates for coagulation therapy.
Fritsma MG
Clin Lab Sci; 2003; 16(2):115-9. PubMed ID: 12757192
[TBL] [Abstract][Full Text] [Related]
8. [Labile blood products and their preparation].
Chabanel A; Folléa G
Rev Prat; 2001 Jun; 51(12):1306-10. PubMed ID: 11503503
[TBL] [Abstract][Full Text] [Related]
9. Leukocyte-poor blood components: issues and indications.
Lichtiger B; Leparc GF
Crit Rev Clin Lab Sci; 1991; 28(5-6):387-403. PubMed ID: 1772586
[TBL] [Abstract][Full Text] [Related]
10. [Techniques of preparation and indications of labile blood products].
Clément S
Transfus Clin Biol; 2011 Apr; 18(2):250-61. PubMed ID: 21474355
[TBL] [Abstract][Full Text] [Related]
11. [Supportive therapy with blood components].
Höcker P
Wien Med Wochenschr; 1991; 141(9-10):209-12. PubMed ID: 1949846
[TBL] [Abstract][Full Text] [Related]
12. [Blood products].
Montloin A
Rev Infirm; 1992 Mar; 42(6):33-41. PubMed ID: 1598492
[No Abstract] [Full Text] [Related]
13. Blood component replacement therapy.
Coffland FI; Sheleton DM
Crit Care Nurs Clin North Am; 1993 Sep; 5(3):543-56. PubMed ID: 8217049
[TBL] [Abstract][Full Text] [Related]
14. Preparation of blood products for transfusion: is there a best method?
Devine DV; Serrano K
Biologicals; 2012 May; 40(3):187-90. PubMed ID: 22119012
[TBL] [Abstract][Full Text] [Related]
15. Blood-component therapy: selection, administration and monitoring.
Chiaramonte D
Clin Tech Small Anim Pract; 2004 May; 19(2):63-7. PubMed ID: 15179925
[TBL] [Abstract][Full Text] [Related]
16. Current opinions on the role of pathogen reduction technology in improving the viral safety of blood and derivatives.
Seghatchian J
Transfus Apher Sci; 2008 Aug; 39(1):49-50. PubMed ID: 18617442
[No Abstract] [Full Text] [Related]
17. [Essential standards of mechanical autologous donation and transfusion].
Paravicini D
Beitr Infusionsther; 1991; 28():341-7. PubMed ID: 1725652
[TBL] [Abstract][Full Text] [Related]
18. [The current potentials for optimal whole-blood transfusion and component therapy with blood products--erythrocytes in obstetrics and gynecology--the indications, means and methods].
Nikolov A; Kovachev I; Gŭrcheva L; Dimitrov A
Akush Ginekol (Sofiia); 1998; 37(4):46-9. PubMed ID: 10360055
[No Abstract] [Full Text] [Related]
19. [Current technologies for blood loss prevention during abdominal hysterectomy].
Fedorova TA; Ragimov AA; Bogomazova IV; Rogachevskiĭ OV; Dzhabrailova DA
Anesteziol Reanimatol; 2007; (6):48-51. PubMed ID: 18326259
[TBL] [Abstract][Full Text] [Related]
20. Blood component therapy in obstetrics.
Fuller AJ; Bucklin B
Obstet Gynecol Clin North Am; 2007 Sep; 34(3):443-58, xi. PubMed ID: 17921009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
